SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics Monthly Activity About

SEC Comment Letter for Nexentis Technologies (NXTS) — Apr 27, 2026

Nexentis Technologies Inc.
Date: April 27, 2026 · CIK: 0001789192 · Accession: 0000000000-26-004273

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-295100

Date
April 27, 2026
Author
Division of
Form
UPLOAD
Company
Nexentis Technologies Inc.

Letter

Re: Nexentis Technologies Inc. Registration Statement on Form S-3 Filed April 16, 2026 File No. 333-295100 Dear David Palach:

April 27, 2026

David Palach Chief Executive Officer Nexentis Technologies Inc. Pinhas Sapir St. 3, Kiryat HaMada Ness Ziona 7403626, Israel

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tim Buchmiller at 202-551-3635 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Michael Soumas, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 April 27, 2026

David Palach
Chief Executive Officer
Nexentis Technologies Inc.
Pinhas Sapir St. 3, Kiryat HaMada
Ness Ziona 7403626, Israel

 Re: Nexentis Technologies Inc.
 Registration Statement on Form S-3
 Filed April 16, 2026
 File No. 333-295100
Dear David Palach:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Tim Buchmiller at 202-551-3635 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Michael Soumas, Esq.
</TEXT>
</DOCUMENT>